Veracyte (VCYT) to Release Earnings on Wednesday

Key Points

• Veracyte (NASDAQ:VCYT) is set to announce its Q2 2025 earnings on August 6, with analysts expecting earnings of $0.31 per share and revenue of $120.90 million.
• The company’s shares opened at $24.47, reflecting a 1-year low of $19.73 and a high of $47.32, while its market capitalization stands at $1.92 billion.
• Recent reports show analysts have mixed views on the stock, with the price targets from various brokerages ranging from $37.00 to $42.00 and an overall average rating of "Moderate Buy".

Veracyte (NASDAQ:VCYT - Get Free Report) is expected to release its Q2 2025 earnings data after the market closes on Wednesday, August 6th. Analysts expect Veracyte to post earnings of $0.31 per share and revenue of $120.90 million for the quarter.

Veracyte Stock Up 0.6%

Shares of NASDAQ:VCYT traded up $0.13 during trading on Friday, hitting $23.64. 1,741,593 shares of the company were exchanged, compared to its average volume of 1,134,447. The business's 50 day moving average is $26.30 and its 200-day moving average is $31.73. The company has a market capitalization of $1.85 billion, a P/E ratio of 57.66 and a beta of 2.07. Veracyte has a 1-year low of $19.73 and a 1-year high of $47.32.

Institutional Trading of Veracyte

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada grew its holdings in Veracyte by 23.3% during the 1st quarter. Royal Bank of Canada now owns 28,712 shares of the biotechnology company's stock worth $852,000 after acquiring an additional 5,435 shares during the period. Intech Investment Management LLC grew its holdings in Veracyte by 54.1% during the 1st quarter. Intech Investment Management LLC now owns 42,762 shares of the biotechnology company's stock worth $1,268,000 after acquiring an additional 15,017 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Veracyte by 12.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 195,793 shares of the biotechnology company's stock worth $5,805,000 after acquiring an additional 21,330 shares during the period. Finally, Jane Street Group LLC grew its holdings in Veracyte by 94.7% during the 1st quarter. Jane Street Group LLC now owns 216,909 shares of the biotechnology company's stock worth $6,431,000 after acquiring an additional 105,499 shares during the period.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Needham & Company LLC lowered their price target on shares of Veracyte from $51.00 to $41.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Wall Street Zen upgraded shares of Veracyte from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Guggenheim lowered their price target on shares of Veracyte from $45.00 to $37.00 and set a "buy" rating for the company in a report on Wednesday, April 9th. Finally, UBS Group lowered their price target on shares of Veracyte from $49.00 to $42.00 and set a "buy" rating for the company in a report on Thursday, May 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $40.90.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.